28 November 2018 - The Global Diabetic
Nephropathy Market is expected to witness significant demand
over the forecast period. Diabetic Nephropathy is a progressive kidney disease
triggered by damage to the capillaries in the kidney glomeruli. The causes of
diabetic nephropathy include factors such as high blood sugar, high
cholesterol, excessive smoking, and advanced glycation end product formation.
In case of the symptoms, there are no symptoms in the early stage. Therefore,
it is important to undergo regular urine tests to discover if there is kidney
damage. Generally, the symptoms appear after the kidney starts damaging. Some
of the late symptoms include nausea, headache, lack of appetite, itchy skin,
severe tiredness, leg swelling, etc.
The
diagnosis is carried out by a test which is based on the measurement of high
levels of a protein namely albumin in the urine. The factors that propel the
growth of the global Diabetic Nephropathy market size include increasing
incidence of diabetes, and growing R&D activities and investments in drug
discovery. In addition, expanding awareness regarding diabetes diseases
treatment and also an upsurge in use of combination therapy is projected to
drive the growth of the global Diabetic Nephropathy market size. On the other hand, there are also factors
that hamper the growth of the market size such as growing number of patent expirations
and strict rules & regulations and time-consuming product authorization
procedures for drugs. The global Diabetic Nephropathy market size is classified
on the basis of treatment type and geography.
On
the basis of treatment type, the global Diabetic Nephropathy market size is
classified as Angiotensin-Converting Enzyme Inhibitors, Antioxidant
Inflammation Modulator, Angiotensin Receptor Blockers, Calcium Channel
Blockers, Connective Tissue Growth Factor Inhibitors, Diuretics, Endothelin-A
Receptor Antagonist, G Protein-Coupled Receptors, Renin Inhibitors and Monocyte
Chemoattractant Proteins Inhibitor. On the basis of geography, the global
Diabetic Nephropathy market size is classified as North America, Latin America,
Western Europe, Eastern Europe, Asia Pacific Excluding Japan, Japan and Middle
East and Africa. The North American
region comprises the U.S., and Canada. Latin America region comprises Mexico,
Brazil, and Rest of Latin America. The Western European region comprises
Germany, Italy, England, Spain, France, Nordic countries, BENELUX, and Rest of
Western Europe. The Eastern European region comprises Russia, Poland, and Rest
of Eastern Europe. Asia Pacific Excluding Japan comprises China, India, ASEAN,
Australia & New Zealand, and Rest of APEJ. The Middle East and Africa
comprises GCC countries, S. Africa, N. Africa, and Rest of MEA.
In
case of geographical region, North America is projected to dominate a major
share of the global Diabetic Nephropathy market. The factors that attribute to
this major share are owed to increased combination drugs usage and also rising
awareness regarding several kidney diseases. The North American market is
followed by Europe; Europe is the second major market of the global Diabetic
Nephropathy market owing to growing incidence of diabetes and rise in
healthcare expenditure for diabetes treatment in the region. On the other hand,
Asia Pacific Excluding Japan market is projected to grow at rapidly during the
forecast period due to presence of large patient pool, increase in disposal for
healthcare treatment and increased awareness regarding novel diabetic drugs in
the market.
Some
of the key players that fuel the growth of the global Diabetic Nephropathy
market include Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis
AG and Sanofi S.A. The prominent other
players include AbbVie Inc., Ampio Pharmaceuticals Inc., OncoImmune Inc.,
Pfizer Inc., IMMD Inc., Mesoblast Ltd., NephroGenex Inc., Questcor
Pharmaceuticals Inc., Reata Pharmaceuticals Inc., GenKyoTex S.A., Astellas
Pharma Inc., Bayer AG, ChemoCentryx Inc., Eli Lilly and Co., Glycadia
Pharmaceuticals Inc., Novo Nordisk A/S, NOXXON Pharma AG, and PhytoHealth Corp.
Market Segment:
Geographically, this report is segmented
into several key Regions, with production, consumption, revenue (million USD),
market share and growth rate of Diabetic Nephropathy in these regions, from
2013 to 2025 (forecast), covering
•
North America
•
Europe
•
China
•
Japan
•
Southeast Asia
•
India
Global Diabetic Nephropathy market competition
by top manufacturers, with production, price, revenue (value) and market share
for each manufacturer; the top players including
•
Novartis AG
•
Eli Lilly
•
Bayer AG
•
Merk
•
Nono Nordisk
•
Mallinckrodt Pharmaceuticals
•
Mitsubishi Tanabe Pharma Corporation
•
Mesoblast Ltd
•
Ampio Pharmaceuticals
•
Reata Pharmaceuticals
•
GenKyoTex S.A
•
ChemoCentryx Inc
Comments
Post a Comment